ClinicalTrials.gg

Program

CPD704

A development code. Also written as “CPD704 Inhalation Suspension”.

In Sino Biopharmaceutical's pipeline, PDE4抑制剂. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 1, since Nov 19, 20251 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 1since Nov 19, 2025Nov 19, 2025none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as CPD704, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 19, 2025First study: phase 1 study in HealthyFirst studyNCT07301203 · 90 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07301203Healthy · China1RecruitingJun 8, 202690

How it is read

Names in the registry

  • “CPD704 Inhalation Suspension”, 1 entry

Codes read as this program: CPD704.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.